Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023056 | 0.86 | ACHE (0.54) | ACHEMEN1THRBKMT2A | |
| SCHEMBL6022686 | 0.86 | MAPT (0.54) | ACHEALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL6023480 | 0.82 | MEN1 (0.57) | ACHEMEN1THRBKMT2A | |
| SCHEMBL6023956 | 0.80 | MEN1 (0.62) | ACHEMEN1THRBKMT2A | |
| SCHEMBL6022932 | 0.79 | MAPT (0.57) | ACHEALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL6022671 | 0.79 | MAPT (0.46) | ALDH1A1SMN1; SMN2MAPTLMNAMEN1 | |
| SCHEMBL6022763 | 0.76 | MAPT (0.44) | ACHEALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL6022755 | 0.76 | MAPT (0.49) | ACHEALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL6022751 | 0.76 | MAPT (0.49) | ACHEALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL24641954 | 0.73 | MAPT (0.83) | ALDH1A1SMN1; SMN2MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078407-B2 | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | HTT, PARK7, NQO1 | ACHE 233/4885ALDH1A1 804/4885SMN1; SMN2 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.